PDCD1 and cancer: Early reports on clinical examination using remedial vaccines in NSCLC have been disappointing, but right now vaccines are being identified with new targeted antigens and adjuvant therapies, and combining the vaccines with anti-PD-1/PD-L1 and anti-CTLA-4 drugs has given vaccines a new chance in cancer treatment (70).